PatentsDB

Method for treatment of blood tumor using anti-TIM-3 antibody

US9487591B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9487591-B2
Application numberUS-201514739154-A
CountryUS
Kind codeB2
Filing dateJun 15, 2015
Priority dateApr 10, 2009
Publication dateNov 8, 2016
Grant dateNov 8, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).

First claim

Opening claim text (preview).

What is claimed is: 1. A method for treating a tumor in a subject, comprising administering an anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) antibody or its TIM-3 binding fragment to the subject who is suspected to have a tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood, wherein the cell is at least one cell fraction of (a) Lin(−)CD34(+)CD38(+) or (b) Lin(−)CD34(−). 2. The method according to claim…

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

View patent family 42936338

External sources

Next steps

Free tools are coming soon. Tell us what you want to track and we'll notify you.

Get alerts for this patentView on Google Patents

Request deeper analysis

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9487591B2 cover?
Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can…
Who is the assignee on this patent?
Kyowa Hakko Kirin Co Ltd, Univ Kyushu Nat Univ Corp
What technology area does this patent fall under?
Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).